Immunoglobulin E specific for Vespula squamosa venom allergens (sIgE (Vespula squamosa))

Immunoglobulin E (IgE) antibodies specific for Vespula squamosa (Southern Yellowjacket) venom epitopes are the key mediators of Type I hypersensitivity reactions following a sting. These antibodies are produced by B cells upon sensitization to venom allergens, most notably Ves s 1 (phospholipase A1) and Ves s 5 (antigen 5) (Source: WHO/IUIS Allergen Nomenclature Database). Once formed, these specific IgE molecules bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon re-exposure to the venom, the allergens cross-link the receptor-bound IgE, triggering the immediate release of inflammatory mediators like histamine, which can lead to systemic anaphylaxis (Source: PubMed, PMID: 12487211). Therapeutic strategies involve either the sequestration of these antibodies using the monoclonal antibody omalizumab or the induction of immune tolerance through venom immunotherapy (VIT). VIT reduces the sensitivity of the IgE-mediated response by promoting the production of blocking IgG4 antibodies (Source: NIH/StatPearls). Monitoring the levels of these specific IgE antibodies is essential for diagnosing venom allergy and assessing the risk of future systemic reactions. These antibodies are also the focus of diagnostic tools such as skin prick tests and in vitro serum assays. Understanding the epitope specificity of these IgE antibodies helps in developing more precise diagnostic components and therapeutic extracts.

Other names

Southern yellowjacket venom-specific IgEAnti-Vespula squamosa IgEVespula squamosa venom-specific IgEsIgE to Vespula squamosa

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils (Source: FDA Omalizumab Label). Venom immunotherapy (VIT) involves the administration of increasing doses of venom allergens to shift the immune response from a Th2-mediated IgE production toward a Th1/Treg-mediated IgG4 production, effectively desensitizing the patient (Source: AAAAI/ACAAI Practice Parameters).